Evidence map›Paper›PMID 34570278›Full record

ReviewCurrent treatment options in oncology2021

How to Sequence Therapies in Mycosis Fungoides.

Caitlin M Brumfiel, Meera H Patel, Pranav Puri, Jake Besch-Stokes, Scott Lester, William G Rule, Nandita Khera, Jason C Sluzevich, David J DiCaudo, Nneka Comfere and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Caitlin M BrumfielDepartment of Dermatology, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA.
Meera H PatelDepartment of Dermatology, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA.ORCID 0000-0001-8174-0382
Pranav PuriDepartment of Dermatology, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA.
Jake Besch-StokesDepartment of Dermatology, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA.
Scott LesterDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
William G RuleDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, USA.
Nandita KheraDivision of Hematology Oncology, Mayo Clinic, Phoenix, AZ, USA.
Jason C SluzevichDepartment of Dermatology, Mayo Clinic, Jacksonville, FL, USA.
David J DiCaudoDepartment of Dermatology, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA.
Nneka ComfereDepartment of Dermatology, Mayo Clinic, Rochester, MN, USA.
N Nora BennaniDivision of Hematology Oncology, Mayo Clinic, Rochester, MN, USA.
Allison C RosenthalDivision of Hematology Oncology, Mayo Clinic, Phoenix, AZ, USA.
Mark R PittelkowDepartment of Dermatology, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA.
Aaron R MangoldDepartment of Dermatology, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA. mangold.aaron@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementChoice of therapy in mycosis fungoides is based on both patient- and lymphoma-specific factors, such as disease characteristics, comorbidities, symptoms and effect on quality of life, potential associated toxicities of therapy, response and tolerance to prior lines of therapy, and convenience and practicality. Generally, we sequence therapies from least toxic, targeted, nonimmunosuppressive to more toxic, immunosuppressive and from single agent to multiple agents, as necessary. If more toxic, immunosuppressive agents are required to alleviate disease burden or symptoms, we generally use them just long enough to control the disease, then transition to a maintenance regimen with less toxic, less immunosuppressive agents.

Indexed as

Biomarkers, TumorClinical Decision-MakingCombined Modality TherapyDisease ManagementDisease SusceptibilityHumansMycosis FungoidesNeoplasm GradingNeoplasm StagingSkin NeoplasmsTreatment OutcomeBiomarkers, TumorCTCLCutaneous oncologyCutaneous T cell lymphomaLymphomaMycosis fungoides

Identifiers

PMID34570278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.